The Observational Health Data Sciences and Informatics (OHDSI) network conducted an expansive analysis encompassing 37.1 million adults with Type 2 diabetes across 14 international databases, published in February 2025
One phase two trial (mean age 58, with no upper age limit) demonstrated mean reduction in body weight of 15.6% in participants taking CagriSema, compared to 5.1% and 8.1% with semaglutide and cagrilintide in monotherapy, respectively, over 32 weeks
Pinch the tissue and inject
Meet with a dietitian 1x1, join virtual Experiences and Workshops, and follow on-demand strength-training videos tailored to all fitness levels. Meet with a dietitian 1x1, join virtual Experiences and Workshops, and follow on-demand strength-training videos tailored to all fitness levels. Join a judgment-free community of people who are also on a GLP-1 through WWs social platform, Connect
While many state Medicaid plans cover Mounjaro for type 2 diabetes, coverage for Zepbound for weight-management use can differ, often requiring prior authorization or meeting specific medical criteria
Key variants including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 correlate with GLP-1 medication response strength and weight loss trajectory
